Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Bendamustine Plus Rituximab (BR) in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma of a Phase 2 Study: Multivariate Analysis and Updated Final Results By Subgroup

Myron S. Czuczman, MD, Andre Goy, MD, Dominick Lamonica, MD, Daniel A. Graf, MD MPH, Mihaela C. Munteanu, MS, Richard H. van der Jagt, MD FRCP(C)

Blood (2014) 124 (21): 1757.

https://doi.org/10.1182/blood.V124.21.1757.1757

Published: 2014

Journal Articles

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

Jorge E. Cortes, MD, Meir Wetzler, MD, Jeffrey H. Lipton, MD, PhD, H. Jean Khoury, MD, Patricia Kropf, MD, Mauricette Michallet, MD, PhD, Michele Baccarani, MD, Delphine Rea, MD, PhD, Charles Chuah, MD, Raghunadharao Digumarti, MD, Purvish M. Parikh, MD, PhD, Elizabeth Li, MS, Mihaela C. Munteanu, MS, Peter D. Brown, DPhil, Franck E. Nicolini, MD, PhD

Blood (2013) 122 (21): 2743.

https://doi.org/10.1182/blood.V122.21.2743.2743

Published: 2013

Journal Articles

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL): The Bright Study

Ian W. Flinn, MD, PhD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, John M. Burke, MD

Blood (2012) 120 (21): 902.

https://doi.org/10.1182/blood.V120.21.902.902

Published: 2012

Journal Articles

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

John M. Burke, MD, Richard H. Van der Jagt, MD, Brad S. Kahl, M.D., Peter Wood, MRCP, Tim E. Hawkins, MBChB, David MacDonald, MD, FRCPC, Mark Hertzberg, MBBS, PhD, Yiu-Lam Kwan, MBBS, David Simpson, MBChB, Michael Craig, MD, Kathryn Kolibaba, MD, Samar Issa, MBChB, FRACP, FRCPA, Richard E. White, PhD, MPH, MBE, Mihaela C. Munteanu, MS, Regina Clementi, RN, MS, Ling Chen, PhD, Ian W. Flinn, MD, PhD

Blood (2012) 120 (21): 155.

https://doi.org/10.1182/blood.V120.21.155.155

Published: 2012

Journal Articles

Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

Nathan H. Fowler, MD, Stephen P. Kahanic, MD, Andres Forero, MD, Mihaela C. Munteanu, MS, Glen L. Davis, MS, Peter Brown, DPhil, Eric Van Den Neste, MD, Fritz C. Offner, MD, PhD, Dominique Bron, MD, Myron S. Czuczman, MD

Blood (2011) 118 (21): 778.

https://doi.org/10.1182/blood.V118.21.778.778

Published: 2011

Journal Articles

Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes,

Christopher Fraser, MD, Patrick A. Brown, MD, Gail C. Megason, MD, Hyo Seop Ahn, MD, Bin Cho, MD, Ivan I. Kirov, MD, Lawrence S. Frankel, MD, Richard Aplenc, MD, MSCE, Debra M. Bensen-Kennedy, MD, Mihaela C. Munteanu, MS, Jennifer Weaver, Paul Harker-Murray, MD, PhD

Blood (2011) 118 (21): 3602.

https://doi.org/10.1182/blood.V118.21.3602.3602

Published: 2011

NARROW

Bendamustine Plus Rituximab (BR) in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma of a Phase 2 Study: Multivariate Analysis and Updated Final Results By Subgroup

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes,

Email alerts

ASH Publications

American Society of Hematology

Bendamustine Plus Rituximab (BR) in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma of a Phase 2 Study: Multivariate Analysis and Updated Final Results By Subgroup

Final Analysis Of The Efficacy and Tolerability Of Subcutaneous Omacetaxine Mepesuccinate, ≥24 Months After First Dose, In Patients With Chronic Phase (CP) Or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML)

Differences in Quality of Life Between Bendamustine Plus Rituximab Compared with Standard First-Line Treatments in Patients with Previously Untreated Advanced Indolent Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma

Open-Label Bendamustine for Pediatric Patients with Relapsed or Refractory Acute Leukemia: Safety and Efficacy Outcomes,

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only